{"id":72338,"date":"2026-08-12T11:38:11","date_gmt":"2026-08-12T03:38:11","guid":{"rendered":"https:\/\/flcube.com\/?p=72338"},"modified":"2026-08-12T11:38:12","modified_gmt":"2026-08-12T03:38:12","slug":"essex-bio-technology-signs-strategic-framework-with-gunze-medical-to-expand-fgf-2-regenerative-medicine-access-across-asia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72338","title":{"rendered":"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Essex Bio-Technology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1061:HKG\">HKG: 1061<\/a>) announced a <strong>strategic collaboration framework agreement<\/strong> with <strong>Gunze Medical Limited<\/strong> to <strong>expand commercial access<\/strong> and <strong>advance joint research<\/strong> in <strong>regenerative medicine and wound care<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-overview\" class=\"wp-block-heading\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Essex Bio\u2011Technology (HKG: 1061) \/ Gunze Medical Limited<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Strategic collaboration framework agreement<\/td><\/tr><tr><td><strong>Focus Areas<\/strong><\/td><td>Regenerative medicine and wound care<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>PRC (existing), Southeast Asia (expanded), Japan (inbound for EssexBio FGF-2 products)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>23 Jul 2026<\/td><\/tr><tr><td><strong>Governance<\/strong><\/td><td>Joint Steering Committee to oversee collaborative initiatives and future projects<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-scope-of-the-framework\" class=\"wp-block-heading\">Scope of the Framework<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Southeast Asia Expansion:<\/strong> The agreement builds upon the parties&#8217; <strong>existing commercial partnership in the PRC<\/strong> and broadens it to <strong>key markets in Southeast Asia<\/strong>.<\/li>\n\n\n\n<li><strong>Japan Entry for FGF\u20112:<\/strong> The framework includes the <strong>extension of Gunze Medical&#8217;s capability and resources to EssexBio<\/strong> for making <strong>inroads with its FGF\u20112 based products into Japan<\/strong> \u2014 one of Asia&#8217;s most regulated and high\u2011value pharmaceutical markets.<\/li>\n\n\n\n<li><strong>Joint Product Development:<\/strong> An initiative <strong>led by Gunze<\/strong> to pursue <strong>joint product development<\/strong>, utilising <strong>EssexBio&#8217;s proprietary FGF\u20112 technology<\/strong> together with <strong>Gunze&#8217;s proprietary products (e.g., PELNAC, PELNAC Gplus)<\/strong> to create <strong>Best\u2011in\u2011Class new product(s)<\/strong> addressing <strong>unmet clinical needs in wound care<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-technology-amp-product-profile\" class=\"wp-block-heading\">Technology &amp; Product Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EssexBio Platform:<\/strong> Proprietary <strong>FGF\u20112 (fibroblast growth factor\u20112)<\/strong> technology, a growth\u2011factor approach that promotes tissue repair and regeneration.<\/li>\n\n\n\n<li><strong>Gunze Portfolio:<\/strong> Established regenerative wound\u2011care products including <strong>PELNAC<\/strong> and <strong>PELNAC Gplus<\/strong>, dermal regeneration templates used in complex wound management.<\/li>\n\n\n\n<li><strong>Combination Logic:<\/strong> Pairing a growth\u2011factor platform with scaffold\u2011based wound\u2011care products creates a potential route to differentiated, Best\u2011in\u2011Class combination offerings.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-governance-amp-execution\" class=\"wp-block-heading\">Governance &amp; Execution<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Joint Steering Committee:<\/strong> The two companies will establish a <strong>joint Steering Committee<\/strong> to <strong>oversee collaborative initiatives and future projects<\/strong> arising from the framework agreement.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asia Wound\u2011Care Growth:<\/strong> Aging populations and rising chronic wound incidence across Asia\u2011Pacific are driving demand for advanced regenerative wound\u2011care therapies.<\/li>\n\n\n\n<li><strong>Complementary Footprints:<\/strong> EssexBio brings established commercial presence in China and regional reach, while Gunze contributes Japan market access and a mature regenerative product portfolio.<\/li>\n\n\n\n<li><strong>Deepened Alliance:<\/strong> Upgrading an existing commercial partnership into a joint\u2011development framework signals a long\u2011term commitment to co\u2011create new products rather than distribute existing ones.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding market expansion, product development, and regulatory pathways under the framework agreement. Actual results may differ due to risks including regulatory approvals, definitive product agreements, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4889,4891,4890,100],"class_list":["post-72338","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-essex-bio-technology","tag-gunze-medical","tag-hkg-1061","tag-medical-aesthetics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to expand commercial access and advance joint research in regenerative medicine and wound care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72338\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia\" \/>\n<meta property=\"og:description\" content=\"Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to expand commercial access and advance joint research in regenerative medicine and wound care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72338\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-12T03:38:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-12T03:38:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72338#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72338\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia\",\"datePublished\":\"2026-08-12T03:38:11+00:00\",\"dateModified\":\"2026-08-12T03:38:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72338\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Essex Bio-Technology\",\"Gunze Medical\",\"HKG: 1061\",\"Medical aesthetics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72338#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72338\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72338\",\"name\":\"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-12T03:38:11+00:00\",\"dateModified\":\"2026-08-12T03:38:12+00:00\",\"description\":\"Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to expand commercial access and advance joint research in regenerative medicine and wound care.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72338#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72338\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72338#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia - Insight, China&#039;s Pharmaceutical Industry","description":"Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to expand commercial access and advance joint research in regenerative medicine and wound care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72338","og_locale":"en_US","og_type":"article","og_title":"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia","og_description":"Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to expand commercial access and advance joint research in regenerative medicine and wound care.","og_url":"https:\/\/flcube.com\/?p=72338","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-12T03:38:11+00:00","article_modified_time":"2026-08-12T03:38:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72338#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72338"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia","datePublished":"2026-08-12T03:38:11+00:00","dateModified":"2026-08-12T03:38:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72338"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Essex Bio-Technology","Gunze Medical","HKG: 1061","Medical aesthetics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72338#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72338","url":"https:\/\/flcube.com\/?p=72338","name":"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-12T03:38:11+00:00","dateModified":"2026-08-12T03:38:12+00:00","description":"Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to expand commercial access and advance joint research in regenerative medicine and wound care.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72338#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72338"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72338#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72338"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72338\/revisions"}],"predecessor-version":[{"id":72340,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72338\/revisions\/72340"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}